Product Description
Mitomycin is used in combination with other medications to treat cancer of the stomach or pancreas that has spread to other parts of the body and has not improved or worsened after treatment with other medications, surgery, or radiation therapy. Mitomycin is a type of antibiotic that is only used in cancer chemotherapy. It slows or stops the growth of cancer cells in your body. (Sourced from: https://medlineplus.gov/druginfo/meds/a682415.html)
Mechanisms of Action: DNA Polymerase Inhibitor,Mitosis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Transitional Cell Carcinoma | Oncology Unspecified | Glaucoma
Known Adverse Events: Abdominal Pain | Flank Pain | Pain Unspecified | Hematuria | Dysuria | Endophthalmitis | Cataract
Company: UroGen Pharma
Company Location: RA'ANANA L3 4365007
Company CEO: Elizabeth Barrett
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, China, Czech Republic, Egypt, Estonia, Finland, France, Georgia, Germany, Israel, Italy, Japan, Korea, Latvia, Lithuania, Netherlands, Poland, Romania, Serbia, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 24
Highest Development Phases
Phase 3: Bladder Cancer|Muscle Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma
Phase 2: Adenocarcinoma|Anal Cancer|Anus Cancer|Head and Neck Cancer|Hepatocellular Carcinoma|Kidney Transplant|Ovarian Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Phase 1: Pterygium
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Rad-IO | P3 |
Unknown status |
Muscle Cancer|Bladder Cancer |
2030-02-07 |
|
| BL011 | P3 |
Unknown Status |
Muscle Cancer|Bladder Cancer |
2028-07-17 |
|
| Study-AB03 | P3 |
Unknown Status |
Bladder Cancer |
2028-06-30 |
|
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of LG IR NMIBC | P3 |
Active, not recruiting |
Bladder Cancer|Muscle Cancer |
2028-03-09 |